UBS Maintains Neutral on CME Group, Raises Price Target to $270
UBS analyst Alex Kramm maintains CME Group (NASDAQ:CME) with a Neutral and raises the price target from $260 to $270.
Share
Why It Matters
An expert analyst thinks CME Group stock is fairly priced right now. They raised their target price slightly, which suggests calm confidence in the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.